Radiation Therapy in Treating Young Patients With Gliomas (NCT00238264) | Clinical Trial Compass
CompletedPhase 2
Radiation Therapy in Treating Young Patients With Gliomas
United States92 participantsStarted 2006-11
Plain-language summary
RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.
Who can participate
Age range3 Years – 20 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed\* low-grade glioma, including any of the following:
* Juvenile pilocytic astrocytoma (JPA) or pleomorphic JPA
* Diffuse astrocytoma, including any of the following subtypes:
* Fibrillary astrocytoma
* Gemistocytic astrocytoma
* Subependymal giant cell astrocytoma
* Pleomorphic xanthoastrocytoma
* Low-grade oligoastrocytoma
* Low-grade oligodendroglioma
* Low-grade glioma not otherwise specified NOTE: \*Patients with chiasmatic lesions who have contiguous extension of tumor into other regions of the visual pathway by CT scan or MRI are eligible without histopathologic confirmation; repeat biopsy required for patients with recurrent tumors that enhance but whose initial tumor did not
* Measurable disease by radiography
* Meets any of the following criteria:
* Progressive nonresectable disease
* Any location in the brain
* Patients with a less than gross total resection are eligible provided they are symptomatic from their tumor OR the risk from neurologic impairment with progression is high enough to warrant immediate treatment
* Has undergone biopsy only
* Must have received ≥ 1 course of prior chemotherapy (for patients \< 10 years of age)
* Prior chemotherapy optional (for patients ≥ 10 years of age)
* No type-1 neurofibromatosis
* No evidence of leptomeningeal dissemination
PATIENT CHARACTERISTICS:
Age
* 3 to 20
Performance status
* ECOG 0-2 OR
* Karnofsky 50-100% (for patie…